First seen Jun 29, 2026 · Updated 1d ago · 2 source items
Patent-cliff exposure at several large-cap pharmas is driving a fresh wave of takeout speculation across mid-cap biotech.
Big-pharma revenue holes are the most reliable driver of biotech M&A premiums.
Moderate expected market impact (relevance 84/100). Most exposed: $PFE, $MRK, $XBI.
The 2028-2031 LOE gap across the top 5 is ~$120B in annual revenue. That capital HAS to buy pipelines. Mid-cap oncology and I&I are the obvious shelves.
♥ 2.0K⇄ 570💬 210👁 289.0K
Patent cliffs put business development back in focus
Investor expectations for biotech acquisitions are rising as loss-of-exclusivity timelines approach.
2d ago · BioPharma Ledger
Patent cliffs put business development back in focus
1d ago · X
The 2028-2031 LOE gap across the top 5 is ~$120B in annual revenue. That capital HAS to buy pipelines. Mid-cap oncology and I&I are the obvious shelves.
Moderate confidence (74/100), supported mainly by cross-source confirmation (66) and limited mainly by engagement depth (52).
Tickers
Topics
Perennial narrative; the LOE math is real but deal timing is unforecastable.